SENSible Question: How Might Cyclarity’s UDP-003 Compare to EDTA Chelation?

A supporter asks us to compare the expected benefits of Cyclarity’s UDP-003 to chelation therapy. Although both target the age-related scourge of atherosclerotic cardiovascular disease (ASCVD), EDTA (if it works) dampens down the worst aspects of having ASCVD, while UPD-003 is a SENS “damage-repair” therapeutic which is expected to remove the underlying damage itself and reverse the disease process.


EoY 2022-LysoSENS

Week Two of our 2022 End of Year Campaign features LysoSENS (Clearing Waste Accumulations Out of Cells) – with a disease focus on Challenging Atherosclerosis. Also featuring videos from Life Noggin, AMA with Dr. Matthew O’Connor and Michael Rae.


Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2023 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also


You can